Diabetes insipidus is a rare condition that causes you to lose too much water through your urine, interfering with proper fluid balance in your body. You can develop diabetes insipidus if you have ...

Transient diabetes insipidus almost always begins within 24-48 h of surgery, and usually abates within several days. Both transient diabetes insipidus and the first phase of the triphasic pattern ...

Eton Pharma announces positive results from bioequivalence study of ET-600 to treat central diabetes insipidus: Deer Park, Illinois Monday, March 17, 2025, 18:00 Hrs [IST] Eton Ph ...

Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a ...

Are you searching for effective medications to treat 'Diabetes Insipidus'? This comprehensive guide provides the latest information on medications-both generic and branded-that are essential for ...

Our experience and that of others demonstrates that this condition has a characteristic presentation – that is, headache, hypopituitarism and diabetes insipidus. When significant mass effect is ...

Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug ...

Eton Pharmaceuticals (ETON) announced positive results from its bioequivalence study of ET-600, a proprietary, patented oral solution of ...

a patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. In a bioequivalence study conducted in 75 human subjects, ET-600 showed pharmacokinetic ...

Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.